PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1

被引:44
作者
Roeb, Wendy
Boyer, Antonia
Cavenee, Webster K.
Arden, Karen C.
机构
[1] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
[4] Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA
关键词
Fkhr; Foxo; p57; Pax; 3; rhabdomyosarcoma;
D O I
10.1073/pnas.0708910104
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The chimeric protein PAX3-FOXO1, resulting from a translocation between chromosomes 2 and 13, is the most common genetic aberration in the alveolar subtype of the human skeletal muscle tumor, rhabdomyosarcoma. To understand how PAX3-FOXO1 contributes to tumor development, we isolated and characterized muscle cells from transgenic mice expressing PAX3-FOXO1 under control of the PAX3 promoter. We demonstrate that these myoblasts are unable to complete myogenic differentiation because of an inability to up-regulate p57Kip2 transcription. This defect is caused by reduced levels of the EGR1 transcriptional activator resulting from a direct, destabilizing interaction with PAX3-FOXO1, Neither PAX3 nor FOXO1 share the ability to regulate p57Kip2 transcription. Thus, the breakage and fusion of the genes encoding these transcription factors creates a unique chimeric protein that controls a key cell-cycle and -differentiation regulator.
引用
收藏
页码:18085 / 18090
页数:6
相关论文
共 54 条
  • [1] Anderson John, 1999, Neoplasia (New York), V1, P340, DOI 10.1038/sj.neo.7900052
  • [2] Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3
    Anderson, MJ
    Shelton, GD
    Cavenee, WK
    Arden, KC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (04) : 1589 - 1594
  • [3] Causes of oncogenic chromosomal translocation
    Aplan, PD
    [J]. TRENDS IN GENETICS, 2006, 22 (01) : 46 - 55
  • [4] Baffa R, 1996, CANCER RES, V56, P268
  • [5] Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma
    Bennicelli, JL
    Edwards, RH
    Barr, FG
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (11) : 5455 - 5459
  • [6] BENNICELLI JL, 1995, ONCOGENE, V11, P119
  • [7] 3 TUMOR-SUPPRESSOR REGIONS ON CHROMOSOME-11P IDENTIFIED BY HIGH-RESOLUTION DELETION MAPPING IN HUMAN NON-SMALL-CELL LUNG-CANCER
    BEPLER, G
    GARCIABLANCO, MA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (12) : 5513 - 5517
  • [8] FKHR (FOXO1a) is required for myotube fusion of primary mouse myoblasts
    Bois, PRJ
    Grosveld, GC
    [J]. EMBO JOURNAL, 2003, 22 (05) : 1147 - 1157
  • [9] High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors
    Bourcigaux, N
    Gaston, V
    Logié, A
    Bertagna, X
    Le Bouc, Y
    Gicquel, C
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (01) : 322 - 330
  • [10] p53 family members in myogenic differentiation and rhabdomyosarcoma development
    Cam, Hakan
    Griesmann, Heidi
    Beitzinger, Michaela
    Hofmann, Lars
    Beinoraviciute-Kellner, Rasa
    Sauer, Markus
    Huettinger-Kirchhof, Nicole
    Oswald, Claudia
    Friedl, Peter
    Gattenloehner, Stefan
    Burek, Christof
    Rosenwald, Andreas
    Stiewe, Thorsten
    [J]. CANCER CELL, 2006, 10 (04) : 281 - 293